erythromycin A

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: erythromycin A
• 英文别名: (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
• 化学式: C₃₇H₆₇NO₁₃
• 分子量: 733.938
• InChiKey: ULGZDMOVFRHVEP-TXJUTXNDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  51
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  194
• 氢给体数：
  5
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  erythromycin A 在 盐酸羟胺 、 氨 、 溶剂黄146 作用下， 以 水 、 异丙醇 为溶剂， 反应 29.0h， 以85%的产率得到erythromycin A-9-oxime
  参考文献：
  名称：

  WO2006/64299

  摘要：

  公开号：

文献信息

• PREPARATION PROCESS OF ERYTHROMYCIN THIOCYANATE
  申请人：Xiong Hui

  公开号：US20140228555A1

  公开（公告）日：2014-08-14

  Disclosed is a preparation process of erythromycin thiocyanate, which belongs to the pharmaceutical field. The preparation process provided by the invention uses erythromycin or its salt(s) as raw material(s), dissolves it/them in acetone or the mixed solvent containing acetone and obtains erythromycin thiocyanate rich in erythromycin thiocyanate A as the main component and low in the content of impurities. Said erythromycin thiocyanate could be used as the raw material for preparing Azithromycin and Clarithromycin, which meets to the standards made by European Union and US.

  揭示了红霉素硫氰酸盐的制备过程，属于制药领域。该发明提供的制备过程使用红霉素或其盐作为原料，将其溶解在丙酮或含丙酮的混合溶剂中，并获得富含红霉素硫氰酸盐A的红霉素硫氰酸盐作为主要成分，杂质含量低。所述的红霉素硫氰酸盐可用作制备阿奇霉素和克拉霉素的原料，符合欧盟和美国制定的标准。
• DEUTERIUM-ENRICHED AZITHROMYCIN
  申请人：Czarnik Anthony W.

  公开号：US20090062220A1

  公开（公告）日：2009-03-05

  The present application describes deuterium-enriched azithromycin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
• PROCESS FOR CELLULAR PRODUCTION OF BIOLOGICALLY ACTIVE COMPOUNDS
  申请人：Weber J. Mark

  公开号：US20100047899A1

  公开（公告）日：2010-02-25

  A process of increasing the cellular production of biologically active compounds is provided. The process is particularly useful for increasing antibiotic production by bacterial cells. The process includes the step of inhibiting the activity of methylmalonyl-CoA mutase.
• COMPOUNDS, POLYMERS AND METHODS FOR TREATING GASTROINTESTINAL DYSFUNCTION
  申请人：Kalivretenos Aristotle G.

  公开号：US20100255062A1

  公开（公告）日：2010-10-07

  The present disclosure describes novel carbon-based diazeniumdiolates agents and compounds or salts or prodrugs thereof that release nitric oxide for the treatment of neuropathic gastrointestinal dysfunction. The neuropathic gastrointestinal dysfunction refers to disorders associated with motility, sensation and neuromuscular function that include but are not limited to conditions such as delayed gastric emptying.
• US8796474B1
  申请人：——

  公开号：US8796474B1

  公开（公告）日：2014-08-05